NCCN Guidelines Version 2.2016 腎癌 - tri-kobe.org

1 NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc. NCCN NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) NCCN 2018 4 2018 4 23 NCCN Guidelines for Patients NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc. NCCN NCCN *Robert J. Motzer, MD/Chair Memorial Sloan Kettering Cancer Center *Eric Jonasch, MD/Vice-chair The University of Texas MD Anderson Cancer Center Neeraj Agarwal, MD Huntsman Cancer Institute at the University of Utah Sam Bhayani, MD Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine William P.

2 Bro Kidney Cancer Association Sam S. Chang, MD Vanderbilt-Ingram Cancer Center Toni K. Choueiri, MD Dana-Farber/Brigham and Women s Cancer Center Brian A. Costello, MD, MS Mayo Clinic Cancer Center Ithaar H. Derweesh, MD UC San Diego Moores Cancer Center Rodney Ellis, MD Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Mayer Fishman, MD, PhD Moffitt Cancer Center Thomas H. Gallagher, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Saby George, MD Roswell Park Comprehensive Cancer Center John L. Gore, MD, MS Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Steven L.

3 Hancock, MD Stanford Cancer Institute Michael R. Harrison, MD Duke Cancer Institute Won Kim, MD UCSF Helen Diller Family Comprehensive Cancer Center Christos Kyriakopoulos, MD University of Wisconsin Carbone Cancer Center Chad LaGrange, MD Fred & Pamela Buffett Cancer Center Elaine T. Lam, MD University of Colorado Cancer Center Clayton Lau, MD City of Hope Comprehensive Cancer Center Andrew McDonald, MD, MS University of Alabama at Birmingham Comprehensive Cancer Center M. Dror Michaelson, MD, PhD Massachusetts General Hospital Cancer Center Thomas Olencki, DO The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phillip M.

4 Pierorazio, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Elizabeth R. Plimack, MD, MS Fox Chase Cancer Center Bruce G. Redman, DO University of Michigan Comprehensive Cancer Center Brian Shuch, MD Yale Cancer Center/Smilow Cancer Hospital Brad Somer, MD St. Jude Children s Research Hospital/ University of Tennessee Cancer Institute Guru Sonpavde, MD University of Alabama at Birmingham Comprehensive Cancer Center Jeffrey Sosman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University NCCN Mary Dwyer, MS Lisa Gurski, PhD Rashmi Kumar, PhD Griselda Zuccarino-Catania, PhD / / * NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc.

5 NCCN NCCN KID-1 I III KID-1 IV KID-2 IV KID-3 KID-4 KID-5 KID-A KID-B KID-C ST-1 NCCN NCCN National Comprehensive Cancer Network NCCN NCCN National Comprehensive Cancer Network NCCN NCCN 2018 NCCN NCCN NCCN 2A NCCN NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc.

6 NCCN NCCN 2018 3 2018 4 KID-3 IV 1 2B KID-4 IV 2A MS-1 NCCN 2018 2 2018 3 MS-1 UPDATES NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc. NCCN UPDATES NCCN 2018 1 2018 2 KID-1 I II III e 2B d III e 50mg/ 4 /2 1 NCCN 2017 2 2018 1 KID-2 IV KID-3 Cabozantinib

7 Active surveillance f 3 KID-C KID-C KID-5 g IMDC KID-C i Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016;17:1317-1324. RANKL KID-4 KID-5 KID-5 HLRCC RCC 2A HLRCC RCC 2A HLRCC KID-C 2 Memorial Sloan Kettering Cancer Center MSKCC International Metastatic Renal Cell Carcinoma Database Consortium IMDC ST-1 AJCC TNM 8 NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc.

8 NCCN 2A NCCN KID-1 f 2B c active surveillance a b c KID-A d III e 50mg/ 4 /2 1 f comprehensive metabolic panel CT a MRI a X MRI a CT a b I pT1a d e 2B KID-3 I pT1b II III IV KID-2 KID-B NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc.

9 NCCN 2A NCCN c KID-3 g 2 cytoreductive nephrectomy IV g KID-3 c KID-A f g KID-2 KID-3 f NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc. NCCN 2A NCCN IV KID-5 KID-3 1 1 )

10 1 2B i -2b 1 h 1 2B Cabozantinib i IL-2 j active surveillancek l NCCN Guidelines for Palliative Care h KID-C i IMDC KID-C j k Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016;17:1317-1324. l RANKL KID-B KID-4 NCCN Guidelines Version 2018 4 04/23/18 2018 National Comprehensive Cancer Network, Inc.